Rethinking delivery routes: oral administration of plant-derived exosome-like nanovesicles reduces the toxicity of intravenous injection

Abstract

Plant-derived exosome-like nanovesicles (PELNs), as an emerging “green” nanoplatform, exhibit broad pharmacological activities, low immunogenicity, and inherent advantages as natural drug carriers. They show great potential in the pharmaceutical, cosmetic, and health supplement sectors. The clinical application of PELNs is heavily contingent on their safety profile, which is intricately linked to the administration route. This opinion compares the safety implications of the two primary routes: oral administration versus intravenous injection. Current evidence indicates that intravenous administration of PELNs triggers complement activation, immune responses, and hepatorenal toxicity; even surface engineering modifications cannot completely eliminate these risks. In contrast, oral administration of PELNs may achieve superior safety by leveraging the gastrointestinal tract’s ability to effectively reduce the immunogenic components. Based on these findings, we advocate for the prioritization of oral delivery in the future development of PELNs, given its superior safety profile for realizing their potential as natural therapeutics and drug delivery systems.

Keywords

Plant-derived exosome-like nanovesicle / intravenous injection / oral administration / biosafety / immunogenicity

References

[1] Regente M,Maldonado AM,Jorrín J.Vesicular fractions of sunflower apoplastic fluids are associated with potential exosome marker proteins.FEBS Lett2009;583:3363-6

[2] An Y,Ma SY.From plant based therapy to plant-derived vesicle-like nanoparticles for cancer treatment: past, present and future.Int J Nanomedicine2025;20:3471-91 PMCID:11927496

[3] Chi J,Song Y.Emerging plant-derived exosome-like particles reveal key therapeutic benefits. A comprehensive review of evidence.Int J Nanomedicine2025;20:12393-411 PMCID:12531310

[4] Cheng Z,Shao W.Advances in plant-derived vesicle like nanoparticles-based therapies for inflammatory diseases.Asian J Pharm Sci2025;20:101052 PMCID:PMC12329537

[5] Feng H,Zhang Y.Plant-derived exosome-like nanoparticles: emerging nanosystems for enhanced tissue engineering.Int J Nanomedicine2024;19:1189-204 PMCID:10859124

[6] Feng Z,Fu J,Yu R.Medicinal plant-derived exosome-like nanovesicles as regulatory mediators in microenvironment for disease treatment.Int J Nanomedicine2025;20:8451-79 PMCID:12227098

[7] Tembo KM,Bolideei M.Exploring the bioactivity of microRNAs originated from plant-derived exosome-like nanoparticles (PELNs): current perspectives.J Nanobiotechnol2025;23:563 PMCID:PMC12344895

[8] Hao S,Hu J,Yuan Y.Bioactive compounds and biological functions of medicinal plant-derived extracellular vesicles.Pharmacol Res2024;200:107062

[9] Zeng M,Tao X,Shen C.Emerging trends in the application of extracellular vesicles as novel oral delivery vehicles for therapeutics in inflammatory diseases.Int J Nanomedicine2024;19:8573-601 PMCID:PMC11345024

[10] Che K,Chen H.Advancing functional foods: a systematic analysis of plant-derived exosome-like nanoparticles and their health-promoting properties.Front Nutr2025;12:1544746 PMCID:PMC11924939

[11] Yang N,Liu H,Lu M.Plant-derived extracellular vesicles in facial aesthetics.Extracell Vesicles Circ Nucl Acids2025;6:651-68 PMCID:PMC12809398

[12] Zhao B,Jiang X.Exosome-like nanoparticles derived from fruits, vegetables, and herbs: innovative strategies of therapeutic and drug delivery.Theranostics2024;14:4598-621 PMCID:PMC11373634

[13] Bai C,Zhang X.Research status and challenges of plant-derived exosome-like nanoparticles.Biomed Pharmacother2024;174:116543

[14] Mu N,Zeng L.Plant-derived exosome-like nanovesicles: current progress and prospects.Int J Nanomedicine2023;18:4987-5009 PMCID:10492547

[15] Kim J,Zhang S.Plant-derived exosome-like nanoparticles and their therapeutic activities.Asian J Pharm Sci2022;17:53-69 PMCID:PMC8888139

[16] Xu G,Fu Z.Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies.Signal Transduct Target Ther2025;10:255 PMCID:PMC12350758

[17] Greening DW,Rai A,Chen M.Clinical relevance of extracellular vesicles in cancer - therapeutic and diagnostic potential.Nat Rev Clin Oncol2025;22:924-52

[18] Li Z,Yin H,Zhang HG.Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression.Sci Rep2018;8:14644 PMCID:PMC6168523

[19] Kim J,Chen S.Anti-glioma effect of ginseng-derived exosomes-like nanoparticles by active blood-brain-barrier penetration and tumor microenvironment modulation.J Nanobiotechnol2023;21:253 PMCID:10401762

[20] Chen Q,Liang Y.Natural exosome-like nanovesicles from edible tea flowers suppress metastatic breast cancer via ROS generation and microbiota modulation.Acta Pharm Sin B2022;12:907-23 PMCID:PMC8897038

[21] Chen L,Cao Y.Oral plant-derived nanomedicines mitigate acetaminophen-induced liver injury by modulating the gut-liver axis and intestinal microbiota metabolism.Small2025;21:e2502001

[22] Wang S,Jiang M.Leveraging polysaccharide-derived nanocarriers to open new horizons in oral vaccine activation.Mater Today Bio2025;35:102300 PMCID:PMC12478073

[23] Liu Y,An D,Liu G.Engineered nanomaterials for overcoming multifaceted gastrointestinal barriers: toward precision oral delivery of therapeutics.Pharmacol Res2025;218:107844

[24] Pabst O.Oral tolerance to food protein.Mucosal Immunol2012;5:232-9 PMCID:PMC3328017

[25] Haroon HB,Farhangrazi ZS,Simberg D.Activation of the complement system by nanoparticles and strategies for complement inhibition.Eur J Pharm Biopharm2023;193:227-40

[26] Gao Z,Yang W.Plant-derived exosome-like nanoparticles: innovative nanomedicine for therapeutic applications.Food Sci Nutr2025;13:e70974 PMCID:12454684

[27] Olugbodi JO,Bako G.Effect of sub-dermal exposure of silver nanoparticles on hepatic, renal and cardiac functions accompanying oxidative damage in male Wistar rats.Sci Rep2023;13:10539 PMCID:PMC10310751

[28] Brodin BA,Hertz HM,Toprak MS.Innate immuno-response to nanoparticle uptake in liver and spleen mimics pathogen infection.Nanomedicine2025;20:2721-31 PMCID:PMC12622318

[29] Suk JS,Kim N,Ensign LM.PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.Adv Drug Delivery Rev2016;99:28-51 PMCID:PMC4798869

[30] Zhang J,Guo L,Mao Z.Chinese herbal medicine-derived extracellular vesicles as novel biotherapeutic tools: present and future.J Transl Med2024;22:1059 PMCID:PMC11587639

[31] Eii MN,Aldridge C.Sustainable practice: prescribing oral over intravenous medications.BMJ.2023;383:e075297

[32] Cheng H,Ma Y,Yang H.Advances in targeted therapy for tumor with nanocarriers: a review.Mater Today Bio2025;31:101583 PMCID:PMC11889621

[33] Fang Z.Plant-derived extracellular vesicles as oral drug delivery carriers.J Control Release2022;350:389-400

[34] Chen X,Lin S.Plant-derived nanovesicles: harnessing nature’s power for tissue protection and repair.J Nanobiotechnol2023;21:445 PMCID:10668476

[35] Zhang M,Prasad M.Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer.Biomaterials2016;101:321-40 PMCID:PMC4921206

[36] Kim J,Kim D.Ginseng-derived exosome-like nanovesicles protect against liver fibrosis by regulating TIMP2 pathways and gut dysbiosis.Asian J Pharm Sci2025;20:101105 PMCID:PMC12720992

[37] Teng Y,Qiu X.Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites.Nat Commun2025;16:1295 PMCID:PMC11790884

[38] Sha A,Xiao W.Plant-derived exosome-like nanoparticles: a comprehensive overview of their composition, biogenesis, isolation, and biological applications.Int J Mol Sci2024;25:12092 PMCID:PMC11593521

[39] Song Y,Yu Q.Exosomes in disease therapy: plant-derived exosome-like nanoparticles current status, challenges, and future prospects.Int J Nanomedicine2025;20:10613-44 PMCID:12410150

[40] Li Y,Zhao H,Chen G.Engineering strategies of plant-derived exosome-like nanovesicles: current knowledge and future perspectives.Int J Nanomedicine2024;19:12793-815 PMCID:11618857

[41] Huang F,Geng X.Interpretation of guidance on non-clinical safety evaluation for nanomedicines.Acta Pharm Sin2023;58:805-14

[42] Chenthamara D,Ramakrishnan SG.Therapeutic efficacy of nanoparticles and routes of administration.Biomater Res2019;23:20 PMCID:PMC6869321

[43] Dad HA,Zhu AQ,Peng LH.Plant exosome-like nanovesicles: emerging therapeutics and drug delivery nanoplatforms.Mol Ther2021;29:13-31 PMCID:PMC7791080

[44] Wang S,Zeng Y.Plant-derived vesicle-like nanoparticles for immunomodulation: Mechanisms and applications.Bioact Mater2026;55:171-204 PMCID:PMC12481952

[45] Thomas J,Sharma N.Recent approaches in nanotoxicity assessment for drug delivery applications: challenges and prospects.Med Drug Discov2025;25:100204